# Junta clínica — PT-pseudo_21e7fa67a79e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_21e7fa67a79e",
  "pid": "PT-pseudo_21e7fa67a79e",
  "task": 1,
  "psa": 11.0,
  "age": 70,
  "months": 3,
  "pirads": "5",
  "psad": 0.108,
  "psav": 2.49,
  "psap": 7.8,
  "vol": 101.95,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.77544403,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "100 kg",
    "height": "183 cm",
    "bmi": "29.9",
    "bp": "123/79 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (29 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory."
    },
    {
      "s": "History",
      "t": "First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Never married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "5 units / week",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 34/35 (severe LUTS)",
  "admin": "Interpreter: not required. Consent for data use: signed.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_21e7fa67a79e
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.108 ng/mL²
  - PSA velocity: 2.49 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 101.95 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.77544403 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.

Vitals: weight 100 kg, height 183 cm, BMI 29.9, BP 123/79 mmHg, HR 72 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2007).

Chief complaint: Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory.

History: First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy.

Patient info: retired postal worker; Never married; Lives alone; adult daughter is primary contact.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 34/35 (severe LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.13 epistemic (95% band 0.37-0.89); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.12: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.53: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.78: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: BIOPSY (weighted vote 0.73 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat biopsy on MRI is mandated if there is a lesion on MRI to confirm histological progression. It also states that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may exclude a repeat biopsy in low-risk disease.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline makes the decision dependent on the MRI findings and PSA density, which are not fully resolved by the panel variables alone. EXPERT-COHORT, the finding that the panel does not determine the decision is correct, but the guideline suggests that the documented grade of the prior biopsy and surveillance history are what decide, which is what the Registrar is tasked to find.

WHAT WE STILL NEED
The prior biopsy finding is documented as "Positive" on the panel, and the specific Gleason or ISUP grade is required to determine the next step according to the guideline.
The documented PSA is 11.0 ng/mL, which is above the threshold of 10 ng/mL mentioned in the search result regarding repeat PSA testing.
The documented PI-RADS score is 5, which is a high-risk finding that must be weighed against the prior biopsy result.
The documented prior-biopsy status is "Positive," which is the key variable the guideline requires to be established.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on establishing the documented grade of the prior biopsy and the surveillance history detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size, zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA trend (rising, flat, or falling) beyond the headline value?
  previous_notes (get_previous_notes) -> What is the documented Gleason/ISUP grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade of the prior positive biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size approximately 28 mm in maximum dimension in the left peripheral zone at the base/mid-gland level.

psa_trend
What is the serial PSA trend (rising, flat, or falling) beyond the headline value?
The serial PSA trend is rising, with values: "Dec 2022: 10.2", "Aug 2023: 9.2", "May 2024: 5.2", "Feb 2025: 11.0".

previous_notes
What is the documented Gleason/ISUP grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?
The documented Gleason/ISUP grade of the prior biopsy is "Gleason 3+4 pathology". There is "not recorded" for the number and dates of biopsy sessions, and "not recorded" for surveillance status.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided the necessary information regarding the prior biopsy and surveillance status.

WHAT THIS SUPPORTS
findings that argue FOR sampling this patient now
PI-RADS 5 lesion in the left peripheral zone (base/mid), consistent with high probability of clinically significant prostate cancer.
PSA velocity of 2.49 ng/mL/yr.

findings that argue AGAINST sampling this patient now
The documented Gleason/ISUP grade of the prior biopsy is "Gleason 3+4 pathology".
Surveillance status is "not recorded".

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 11.00 ng/mL over 4 points spanning 26 months; velocity -0.19 ng/mL per year; no meaningful doubling time.
PROJECTION at 6 months: 24.0 ng/mL, conformal 95% band 6.9-83.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.14 epistemic (95% band 0.36-0.89), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.73  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.63 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have answered the moderator's questions regarding the prior biopsy grade and surveillance status.

ALIGNMENT WITH THE PANEL
The retrieved information, specifically the "Gleason 3+4 pathology" from previous_notes, aligns with the panel's decision to recommend biopsy, as the panel protocol noted that the documented prior grade was "none recorded," leading the experts to rely on their weighted vote.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade of the prior positive biopsy? Answered by the Registrar: "Gleason 3+4 pathology".
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the Registrar: "not recorded".

WHAT CARRIES WEIGHT, AND WHY
The documented Gleason/ISUP grade is the most critical variable as it directly informs the guideline-based decision regarding repeat biopsy, which the EAU guideline emphasizes. The lack of recorded surveillance status is also highly relevant as it impacts the risk stratification.

MY SUGGESTION TO THE CHAIR
Given the documented Gleason 3+4 pathology and the rising PSA trend, the evidence supports proceeding with a biopsy to confirm histological progression, as per the panel's weighted consensus.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

70y male, PSA 11.0, PI-RADS 5, prior positive biopsy with unrecorded grade. Rising PSA trend and new lesion size warrant sampling to determine management. Lack of prior grade documentation makes biopsy necessary to guide treatment decision.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
